Mechanistically, a low proportion of PD-1+ and CD8+ TILs co-expressed may underlie the low response rates to PD-1/PD-L1 inhibitors in EGFR-/ALK-positive NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.